7-hydroxystaurosporine

7-hydroxystaurosporine and Topotecan Hydrochloride in Treating Patients With Relapsed or Progressed Small Cell Lung Cancer

UCN-01 and Topotecan in Treating Patients With Recurrent Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cavity Cancer

Combination Chemotherapy in Treating Patients With Chronic Lymphocytic Leukemia or Lymphocytic Lymphoma

UCN-01 and Topotecan in Treating Patients With Recurrent, Persistent, or Progressive Advanced Ovarian Epithelial, Primary Peritoneal, or Fallopian Tube Cancer

UCN-01 and Prednisone in Treating Patients With Solid Tumors or Lymphoma

UCN-01, Fluorouracil, and Leucovorin in Treating Patients With Metastatic or Unresectable Solid Tumors

UCN-01 and Fludarabine in Treating Patients With Recurrent or Refractory Lymphoma or Leukemia

A Phase II Study of UCN-01 in Metastatic Melanoma

UCN-01 in Treating Patients With Advanced or Metastatic Kidney Cancer

7-Hydroxystaurosporine and Irinotecan Hydrochloride in Treating Patients With Metastatic or Unresectable Solid Tumors or Triple Negative Breast Cancer (Currently Accruing Only Triple-negative Breast Cancer Patients Since 6/8/2007)

7-Hydroxystaurosporine and Perifosine in Treating Patients With Relapsed or Refractory Acute Leukemia, Chronic Myelogenous Leukemia or High Risk Myelodysplastic Syndromes

7-hydroxystaurosporine and Cisplatin in Treating Patients With Advanced Malignant Solid Tumors

UCN-01 and Carboplatin in Treating Patients With Advanced Solid Tumors

UCN-01 and Fluorouracil in Treating Patients With Metastatic Pancreatic Cancer

Fluorouracil Plus UCN-01 in Treating Patients With Advanced or Refractory Solid Tumors

UCN-01 and Gemcitabine in Treating Patients With Unresectable or Metastatic Pancreatic Cancer

UCN-01 and Irinotecan in Treating Patients With Advanced Solid Tumors

UCN-01 in Treating Patients With Advanced Cancer

UCN-01 and Cisplatin in Treating Patients With Advanced or Metastatic Solid Tumors